FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies Source: FDA Press Releases

Continue ReadingFDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies

FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests

The U.S. Food and Drug Administration today announced its Commissioner’s National Priority Voucher (CNPV) program to enhance the health interests of Americans. Source: FDA Press Releases

Continue ReadingFDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests